{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:25:14Z","timestamp":1790357114332,"version":"4.1.0"},"reference-count":30,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"5","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Circulating tumor DNA (ctDNA) is a promising biomarker for cancer detection, treatment selection, and disease monitoring. As a result, an increasing number of diagnostic developers are pursuing liquid biopsy assays using next-generation sequencing (NGS) to detect ctDNA. To support clinical adoption, these assays must undergo rigorous analytical validation (AV) to facilitate regulatory approval, support market entry, and ultimately improve outcomes for patients with cancer. To this end, the BLOODPAC AV Working Group developed and published a set of generic AV protocols in September 2020. These included 11 protocols and 4 standard methods designed as a foundational resource for in vitro diagnostic developers, support validation discussions with regulatory bodies, promote alignment between pharmaceutical and diagnostic partners, and help reduce regulatory review cycles by standardizing expectations for study design. In 2023, after over 2 years of practical application, BLOODPAC launched an open comment period (April\u2013July 2023) to gather user feedback. Nine institutions provided comments, which were reviewed by the Working Group and aggregated with feedback received from the (US) Food and Drug Administration via presubmission process. This input informed the development of the updated version to ensure the protocols remain practical, scientifically robust, and aligned with current technologies. This paper outlines the feedback process, reviews key challenges identified, and summarizes the resulting changes. It presents the second iteration (version 2.0) of the BLOODPAC generic AV protocols, reaffirming the consortium's commitment to maintaining their relevance, usability, and scientific rigor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-25-01243","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T19:59:11Z","timestamp":1778529551000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":3,"title":["Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based Circulating Tumor DNA Assays, Version 2.0"],"prefix":"10.1200","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6379-7999","authenticated-orcid":true,"given":"Angela","family":"Silvestro","sequence":"first","affiliation":[{"name":"GSK, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9423-8305","authenticated-orcid":true,"given":"Jonathan","family":"Baden","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Lawrence Township, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Billings","sequence":"additional","affiliation":[{"name":"Streck, La Vista, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli","family":"Bramlett","sequence":"additional","affiliation":[{"name":"Quest Diagnostics, Secaucus, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Corner","sequence":"additional","affiliation":[{"name":"Bio-Rad, Pleasanton, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6798-1408","authenticated-orcid":true,"given":"Tyler","family":"Danek","sequence":"additional","affiliation":[{"name":"Tempus AI, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Deras","sequence":"additional","affiliation":[{"name":"Formerly with Illumina, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dickey","sequence":"additional","affiliation":[{"name":"Labcorp (PGDx), Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Godsey","sequence":"additional","affiliation":[{"name":"Formerly with Quest Diagnostics, Secaucus, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Guan","sequence":"additional","affiliation":[{"name":"Illumina, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8175-4562","authenticated-orcid":true,"given":"Tyler","family":"Hutchinson","sequence":"additional","affiliation":[{"name":"Freenome, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3173-6910","authenticated-orcid":true,"given":"Donald J.","family":"Johann","sequence":"additional","affiliation":[{"name":"University of Arkansas, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1515-0952","authenticated-orcid":true,"given":"Jerry S.H.","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ho Jimmy","family":"Lin","sequence":"additional","affiliation":[{"name":"Freenome, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7437-5177","authenticated-orcid":true,"given":"Jennifer S.","family":"Lococo","sequence":"additional","affiliation":[{"name":"Illumina, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1415-3135","authenticated-orcid":true,"given":"Dorys","family":"Lopez Ramos","sequence":"additional","affiliation":[{"name":"BLOODPAC, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron O.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Freenome, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3961-2739","authenticated-orcid":true,"given":"Daniel","family":"Stetson","sequence":"additional","affiliation":[{"name":"Astrazeneca, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wenz","sequence":"additional","affiliation":[{"name":"Illumina, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4374-7246","authenticated-orcid":true,"given":"Lauren C.","family":"Leiman","sequence":"additional","affiliation":[{"name":"BLOODPAC, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06225-y"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.520"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11815"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0047"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408617"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaa164"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1747"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70227"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2022.12.003"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2025.06.008"},{"key":"e_1_3_8_12_2","unstructured":"U.S. Food and Drug Administration (FDA): Premarket approval (PMA) for COBAS EGFR MUTATION TEST (PMA #P120019). https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P120019"},{"key":"e_1_3_8_13_2","unstructured":"U.S. Food and Drug Administration (FDA): Premarket approval (PMA) for therascreen PIK3CA RGQ PCR kit (PMA #P190004). https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P190004"},{"key":"e_1_3_8_14_2","unstructured":"U.S. Food and Drug Administration (FDA): Premarket approval (PMA) for Guardant360 CDx (PMA #P200010). https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=p200010"},{"key":"e_1_3_8_15_2","unstructured":"U.S. Food and Drug Administration (FDA): Premarket approval (PMA) for FoundationOne liquid CDx (F1 liquid CDx) (PMA #P200006). https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=p200006"},{"key":"e_1_3_8_16_2","unstructured":"U.S. Food and Drug Administration (FDA): Premarket approval (PMA) for RESOLUTION ctDx FIRST (PMA #P210040). https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P210040"},{"key":"e_1_3_8_17_2","unstructured":"U.S. Food and Drug Administration (FDA): Device classification under section 513(f)(2)(De novo) for device PGDx elio plasma focus Dx (Den #DEN230046). https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?id=DEN230046"},{"key":"e_1_3_8_18_2","volume-title":"Clinical & Laboratory Standards Institute: CLSI Guidelines","author":"CLSI","unstructured":"CLSI: Clinical & Laboratory Standards Institute: CLSI Guidelines. https:\/\/www.clsi.org\/"},{"key":"e_1_3_8_19_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for non-small cell lung cancer V.4.2025","year":"2025","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for non-small cell lung cancer V.4.2025. To view the most recent and complete version of the guideline. 2025. https:\/\/www.nccn.org"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.017"},{"key":"e_1_3_8_21_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Colon Cancer V.3.2025","year":"2025","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Colon Cancer V.3.2025. To view the most recent and complete version of the guideline. 2025. https:\/\/www.nccn.org"},{"key":"e_1_3_8_22_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancer V.4.2025","year":"2025","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancer V.4.2025. To view the most recent and complete version of the guideline. 2025. https:\/\/www.nccn.org"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00338"},{"key":"e_1_3_8_24_2","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Rectal Cancer V.2.2025. To view the most recent and complete version of the guideline 2025. https:\/\/www.nccn.org"},{"key":"e_1_3_8_25_2","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Oncology Center of Excellence (OCE) Center for Devices and Radiologic Health (CDRH) Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Use Circulating Tumor DNA Curative-Intent Solid Tumor Drug Development Guidance Industry. 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-circulating-tumor-deoxyribonucleic-acid-early-stage-solid-tumor-drug-development-guidance"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2023.09.004"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-025-00799-7"},{"key":"e_1_3_8_28_2","first-page":"EP39","volume-title":"A Hierarchical Approach to Selecting Surrogate Samples for the Evaluation of In Vitro Medical Laboratory Tests","author":"CLSI","year":"2021","unstructured":"CLSI: A Hierarchical Approach to Selecting Surrogate Samples for the Evaluation of In Vitro Medical Laboratory Tests, 2021. pp EP39-Ed1."},{"key":"e_1_3_8_29_2","volume-title":"Driving Innovation in Liquid Biopsy to Advance Cancer Care","author":"BLOODPAC","unstructured":"BLOODPAC: Driving Innovation in Liquid Biopsy to Advance Cancer Care. https:\/\/www.bloodpac.org"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2025.100301"},{"key":"e_1_3_8_31_2","volume-title":"Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program; Guidance for Industry and Food and Drug Administration Staff","author":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research","year":"2025","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research: Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program; Guidance for Industry and Food and Drug Administration Staff. 2025"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-25-01243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T19:59:18Z","timestamp":1778961558000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-25-01243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1200\/PO-25-01243"],"URL":"https:\/\/doi.org\/10.1200\/po-25-01243","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2501243"}}